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A commentary on
Agitation predicts response of depression to botulinum toxin treatment in a randomized
controlled trial
by Wollmer MA, Kalak N, Jung S, de Boer C, Magid M, Ruichenberg JS, et al. Front Psychiatry (2014)
5:36. doi: 10.3389/fpsyt.2014.00036
Major depressive disorder (MDD) is a mental disorder, characterized by low mood, lack of interest
or pleasure, and a cluster of other vegetative and cognitive symptoms, occurring for a period of
time and causing significant distress or impairment of functioning. It has a relapsing and recurring
course, sometimes becomes chronic. It is a common disorder with a life time prevalence of 16.6%
(1) and 12months prevalence of 6.7% (2). MDD affects patients’ functioning and is associated with
significant personal and societal burden.
It was predicted that MDD would rank second by disability adjusted life years (DALY) among
all disorders worldwide in year 2020, contributing with 5.7% of DALY and second only to ischemic
heart disease (3).
The episodes of depression inMDD, if left untreated,may last formonths or years. There aremany
treatments available for depression including psychotherapy (4), pharmacotherapy (5), neurostim-
ulation (6), and other complementary and alternative medicine methods (7), as summarized in the
CANMAT clinical practice guidelines. Although there are numerous treatments available, the results
are far from ideal, with significant proportion of patients not achieving remission and continuing to
suffer with symptoms of the disorder and functional impairment. Therefore, the quest for new and
better treatment approaches is continuing.
There is a small but growing body of evidence suggesting that botulinum toxin may be useful for
treatment of depression. Botulinum toxin is a protein produced by Clostridium Botulinum and is
highly toxic and lethal. In medical use, when injected, it induces strong flaccid muscle paralysis, and
this effect is used in the treatment of a variety of different disorders characterized by muscle over
activity and spasticity and in hyperhidrosis. More recently, botulinum toxin use has skyrocketed in
cosmetic medicine, where it leads to significant visual improvement of wrinkles, due to the paralysis
of the underlying muscles.
The main hypothesis for the proposed beneficial effects of botulinum toxin in depression
is through the facial feedback. Low mood and depression are often associated with sad facial
expression. It has long been observed that MDD patients often have deep vertical frown lines and
different signs, such as “omega melancholicum” sign and Veraguth’s folds, have been described (8).
Injecting botulinum toxin and improving facial expression would lead to improvement of symptoms
of depression.
In an open study of botulinum toxin injected into the frown muscles of 10 depressed
patients, Finzi and Wasserman (9) reported that 8 of the 10 patients went into
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remission after one treatment of botulinum toxin. This obser-
vation was followed by a small randomized, double blind, con-
trolled trial by Wollmer et al. (10), who examined 30 patients
randomly assigned to receive injection of botulinum toxin or
saline placebo. The patients were mainly women and the authors
reported response rate [as measured by 50% improvement on
HamiltonDepression Rating Scale (HAM-D)] of 60% in the active
group vs 13.3% in the placebo group. Of interest, the presence
of significant vertical frown line was required in order to be
included in this study. Soon after, a larger randomized controlled
trial was reported by Finzi and Rosenthal (11), which included
85 patients. This study used Montgomery–Asberg Depression
Rating Scale (MADRS) as the primary outcome measure and
did not require a pronounced vertical frown for inclusion in
the study, but the results were very similar to the study by
Wollmer. One issue discussed in both randomized and con-
trolled trials was the fact that most patients guessed correctly
whether they were in the placebo group or in the botulinum
toxin active group, which might have also influenced their
response rates.
In the current post hoc analysis (12) of their original study
(10), Wollmer et al. are trying to determine predictors for better
response to botulinum toxin in patients with MDD. After con-
ducting further analysis of the data, they found that high baseline
agitation (asmeasured on item 9 ofHAM-D) is themain predictor
of response to botulinum toxinwith sensitivity of 100%, specificity
of 56%, and overall precision of 87%. Agitation may be associated
with more dynamic motor activity, leading to more changes in the
facial expression. The baseline appearance of the glabellar frown
line was not a predictor in this analysis.
All the limitations of this study (e.g., small size, post hoc anal-
ysis, etc.) are known and clearly stated. Nevertheless, this type of
analysis brings an important clinical point: we not only need to
know which treatment works, but also who are the patients that
would likely benefit most! The authors are to be commended on
this fine attempt to answer that.
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